Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...

An international team, led by Paul R. Fortin of Université Laval, has just identified three markers that would allow for establishing, right at the time of diagnosis, the risk of a lupus ...

This autoimmune disease may impact your skin as well as your nails and hair. Learn what to look for to treat lupus more effectively.

In patients with systemic lupus erythematosus, impaired upper limb function and difficulty performing daily activities are linked to various quality-of-life domains.

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, according to a press release from manufacturer Biogen. Litifilimab (Biogen) is a ...

Litifilimab is a humanized IgG1 monoclonal antibody targeting the BDCA2 receptor to reduce proinflammatory mediators in cutaneous lupus erythematosus.

In a new case report, investigators recommend that in women with systemic lupus erythematosus (SLE), physicians must work closely with the woman to determine whether in vitro fertilization (IVF, a ...

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...